Nexon Pharma Sp. z o.o.

Who owns Nexon Pharma Sp. z o.o.?
Three individuals: Marzena Teresa Idzikowska (40 percent), Agata Matylda Zalega-Bernaciak (30 percent), and Slawomir Radoslaw Bernaciak (30 percent), per National Court Register filings.

Is Nexon Pharma publicly traded?
No. It is a private limited liability company with PLN 5,000 share capital and no exchange listing.

When was the company founded?
It was entered in the National Court Register on December 13, 2016, in Warsaw.

What does Nexon Pharma make?
Dietary supplements and medical devices, including the Mediprolac probiotic family, Islandzki Medic+ throat products, Euphrasia eye drops, and a range of vitamins and specialty supplements.

Where is Nexon Pharma based?
At ul. Chelmzynska 249 in the Rembertow district of Warsaw, Poland, where its offices and group warehousing operate.

Does Nexon Pharma only sell its own brands?
No. In addition to own-brand products, the company group provides pharmaceutical warehousing and distribution, contract manufacturing support, and market analysis services.

Nexon Pharma Sp. z o.o. was entered in the National Court Register on December 13, 2016, by the District Court for the City of Warsaw, XIII Commercial Division. Its registered articles were executed days earlier, on December 9, 2016.

The company was capitalized modestly at PLN 5,000, divided into 100 shares across the three founding partners. Its initial tax registration followed in early January 2017, and the companion limited partnership was registered shortly after with tax number 9522158495.

The founding concept was a family-health product portfolio: supplements and medical devices built on established formulations, priced accessibly, and sold only through pharmacies. The pharmacy-exclusive channel was a strategic choice, aligning the company with pharmacist recommendation rather than competing for supermarket shelf space.

Product development proceeded along several lines. The Mediprolac probiotic family grew into a multi-variant range including children's drops and immune formulations. Islandzki Medic+ built a throat-care line of syrup, spray, and lozenges on Icelandic moss extract. Euphrasia brought medical device eye drops. Standard vitamins, biotin, sleep, and lipid products completed the catalog.

Service lines developed in parallel. The company offers pharmaceutical warehousing and distribution through its group, market analysis for outside firms evaluating the Polish pharmacy market, and contract manufacturing support for companies building new supplement and medical device brands.

Registry records show the company has remained active and in good standing, with its most recent KRS entries filed in June 2026.